Real-world data: nivolumab combo before lung cancer surgery shows promise in argentina

NCT ID NCT07141563

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from Argentina looked at 70 patients with resectable non-small cell lung cancer who received nivolumab (Opdivo) plus chemotherapy before surgery. Researchers wanted to see how well this combination works in real-world practice, measuring how many patients had no cancer left after surgery. The study is observational, meaning it only reviewed past medical records, so it cannot prove the treatment caused the outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) plus platinum-based chemotherapy
What this could lead to: If results are positive, this could support using this combination before surgery for lung cancer in real-world settings.
What could go wrong: This is a small, retrospective study (just 70 people) that looks back at past data, so it cannot prove cause and effect. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC)

Buenos Aires, C1426CPU, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.